Astellas Pharma (4503) AI Stock Analysis

• Market Cap: ¥2.52T
• Dividend Yield: 5.28%
• Average Volume (3M): 4.86M
• Price to Earnings (P/E): 49.5
• Beta (1Y): 0.50
• Revenue Growth: 19.25%
• EPS Growth: 294.48%
• Country: JP
• Employees: 14,754
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - General
• EPS (TTM): 41.84
• Shares Outstanding: 1,809,663,100
• 10 Day Avg. Volume: 5,414,380
• 30 Day Avg. Volume: 4,857,816
• PEG Ratio: -1.81
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,694.30
• Price Target Upside: 20.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 74 Outperform
• Price Target: ¥1,570.00 ▲(11.98%Upside)

Astellas Pharma's overall stock score is driven by strong financial performance and positive earnings call sentiment, reflecting substantial revenue growth and strategic brand expansion. While the company's valuation appears high, the attractive dividend yield partially offsets this concern. Technical indicators show neutral trends, suggesting stable but cautious market sentiment.

Positive Factors

Earnings Projections

Future earnings will be the catalysts with projected EPS growth of 37% CAGR 2024-2027.

Growth Trajectory

Padcev's growth acceleration is redefining Astellas's growth trajectory.

Negative Factors

Loss of Exclusivity Impact

Astellas's bottomline should weather Xtandi LOE better than the topline.

Astellas Pharma Business Overview & Revenue Model

Company Description

Astellas Pharma Inc. is a leading global pharmaceutical company headquartered in Tokyo, Japan, primarily engaged in the research, development, manufacture, and marketing of innovative pharmaceutical products. The company focuses on therapeutic areas such as oncology, urology, immunology, neuroscience, and cardiovascular diseases, providing advanced healthcare solutions to improve the health and well-being of people worldwide.

How the Company Makes Money

Astellas Pharma generates revenue primarily through the sale of its pharmaceutical products, which include both patented and generic drugs. The company's key revenue streams come from its core therapeutic areas, with oncology and urology products being significant contributors. Astellas invests heavily in research and development to innovate and expand its product pipeline, which helps maintain its competitive edge and market share. Additionally, strategic partnerships and licensing agreements with other pharmaceutical and biotech companies enhance its product offerings and market reach, further contributing to its earnings. The company's global presence, with a strong foothold in markets across Japan, the Americas, Europe, and Asia, also plays a crucial role in its revenue generation.

Astellas Pharma Financial Statement Overview

Summary

Astellas Pharma shows strong financial performance with notable revenue growth, a high gross profit margin, and improved net profit margin. Cash flow generation is robust, supporting liquidity and financial flexibility. However, operational efficiency could be enhanced, as indicated by a slight decrease in EBIT margin.

Income Statement

Astellas Pharma demonstrates strong revenue growth with a 19.22% increase from 2024 to 2025. The gross profit margin remains high at 74.57% for 2025, indicating effective cost management. The net profit margin improved significantly from 1.06% in 2024 to 2.65% in 2025. However, the EBIT margin slightly decreased to 13.37% in 2025, suggesting potential challenges in operational efficiency. Overall, the company shows strong growth and profitability trends.

Balance Sheet

Astellas Pharma maintains a solid equity base with an equity ratio of 45.32% in 2025. The debt-to-equity ratio improved to 0.55, reflecting a decrease in leverage and financial risk. Return on Equity (ROE) increased to 3.35% in 2025, indicating better utilization of shareholders' equity. Despite the improvements, the relatively low ROE suggests there is room for enhancing shareholder value.

Cash Flow

The company exhibits robust cash flow generation, with a free cash flow growth rate of 82.95% from 2024 to 2025. The operating cash flow to net income ratio is 3.97, reflecting strong cash flow relative to net income. The free cash flow to net income ratio is 3.24, indicating effective conversion of profits into cash. These metrics highlight Astellas Pharma's strong liquidity and financial flexibility.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.91T	1.60T	1.52T	1.30T	1.25T
Gross Profit	1.43T	1.31T	1.23T	1.04T	1.00T
EBITDA	248.30B	195.34B	240.46B	241.03B	219.83B
Net Income	50.75B	17.05B	98.71B	124.09B	120.59B
Balance Sheet
Total Assets	3.34T	3.57T	2.46T	2.33T	2.27T
Cash, Cash Equivalents and Short-Term Investments	188.37B	335.69B	396.62B	337.28B	331.69B
Total Debt	831.43B	1.01T	200.01B	212.74B	278.26B
Total Liabilities	1.83T	1.97T	948.56B	872.09B	887.51B
Stockholders Equity	1.51T	1.60T	1.51T	1.46T	1.39T
Cash Flow
Free Cash Flow	164.61B	89.98B	239.23B	181.00B	229.40B
Operating Cash Flow	201.61B	172.47B	327.77B	257.44B	306.84B
Investing Cash Flow	-96.52B	-845.80B	-84.50B	-62.41B	-81.89B
Financing Cash Flow	-261.37B	614.06B	-195.62B	-216.30B	-229.48B

Astellas Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1402.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4503, the sentiment is Positive. The current price of 1402 is above the 20-day moving average (MA) of 1393.90, above the 50-day MA of 1387.82, and below the 200-day MA of 1500.14, indicating a neutral trend. The MACD of -3.24 indicates Positive momentum. The RSI at 54.22 is Neutral, neither overbought nor oversold. The STOCH value of 75.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4503.

Astellas Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4507	80 Outperform	$2.23T	12.65	12.99%	2.29%	0.73%	7.75%
4519	79 Outperform	$12.36T	30.15	22.80%	3.33%	17.96%	25.65%
4503	74 Outperform	¥2.52T	49.46	3.22%	5.28%	19.25%	294.48%
4528	72 Outperform	¥725.61B	14.50	6.25%	5.18%	-3.14%	-59.94%
4523	72 Outperform	$1.15T	24.90	5.34%	3.92%	6.42%	10.82%
4568	67 Neutral	¥6.15T	21.14	17.60%	1.82%	17.77%	49.34%
Sector *	65 Neutral	¥345.58B	10.59	-2.88%	2.67%	11.80%	-6.84%

Astellas Pharma Corporate Events

Astellas Pharma Continues Performance-linked Stock Schemes for Executives

Astellas Pharma Inc. announced the continuation of its Performance-linked Stock Compensation and Stock Delivery Schemes for its executives, aimed at aligning management incentives with the company’s long-term value growth. These schemes, which include the BIP Trust for corporate executives and the ESOP Trust for group executives, are designed to enhance transparency and focus on increasing enterprise and shareholder value.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025

Astellas Pharma has announced the continuation of its Performance-linked Stock Compensation Scheme for fiscal year 2025, aimed at incentivizing its directors. This scheme, which employs a Board Incentive Plan (BIP) Trust, aligns executive compensation with the company’s long-term growth and shareholder value, reflecting a strategic focus on enhancing enterprise value.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

Astellas Pharma Announces Changes to Board of Directors

Astellas Pharma Inc. has announced a significant change in its Board of Directors, proposing the appointment of Andreas Busch and Mark Enyedy as new candidates at its upcoming Annual Shareholders Meeting. This move is intended to enhance the board’s diversity and effectiveness, reflecting stakeholder input and aiming to strengthen the company’s position in the global pharmaceutical industry.

Astellas Pharma Reports Higher Than Expected Financial Results

Astellas Pharma reported an increase in other income due to changes in the fair value of contingent consideration related to its clinical development plans and program discontinuations. The company’s actual financial results for the fiscal year ended March 31, 2025, exceeded forecasts, with significant increases in operating profit and profit before tax, reflecting strong operational performance.